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Respiratory tract infections 
Clinical cases 
A B S T R A C T   
Framework: The inappropriate use of antibiotics for respiratory tract infections is dispersed worldwide, thus being 
a strong contributor to antibiotic resistances. As the use of educational interventions among health practitioners 
is shown to have an impact on judicious antibiotic use, an online course (eHealthResp) has been developed, 
especially targeted to pharmacists and physicians. Thus, the main goal of this study is to validate the contents of 
the online course eHealthResp. 
Methods: This two-round Delphi study involved the recruitment of a multidisciplinary panel (n = 19), to which 
the questionnaires of the first round were sent. After the first round, a report summing up the results has been 
forwarded to the panel, along with a new, reformulated version of the questionnaire. 
Results: After the two rounds of the Delphi process, consensus was evaluated. Six clinical cases and fifty-one 
treatments obtained minor consensus [60–75%] or full consensus (≥75%). The question on antibiotic practice 
has obtained a consensus >90% on both rounds. 
Conclusions: The validation of the contents based on experts’ consensus has been an essential approach to 
improve eHealthResp’s online course, as valuable feedback has been provided by the panel on both rounds.   
1. Introduction 
Antibiotic resistance (ABR) is currently one of the major Public 
Health threats worldwide, having as leading cause of new bacterial 
resistance mechanisms the inappropriate use of antibiotics [1,2]. In 
response to this global public health threat, several national and inter-
national actions and initiatives have been developed in recent years 
aiming to strengthen health systems and surveillance, reduce antibiotics 
misuse, and improve ABR prevention [1,2]. Respiratory tract diseases, 
particularly infections of the respiratory tract, constitute one of the 
leading causes of death and disability in the world [3,4]. These highly 
incident respiratory tract infections are predominantly caused by virus 
[5]. The inadequate use and overuse of antibiotics has shown to be very 
common in respiratory tract [6], being dispersed worldwide [7–11], 
rising up to two-thirds of prescribed antibiotics [8]. 
Healthcare quality can be improved using educational interventions 
among health practitioners [12], especially when using digital health 
tools [13,14], ultimately helping to minimise the gap between optimal 
practice and actual clinical care. Among other benefits, the impact of 
these interventions is deeply reflected in the reduction of both medi-
cation errors [15–17] and antibiotic prescription [18,19]. Furthermore, 
studies have demonstrated the positive impact that e-health tools have 
on antibiotic prescription and on its conscientious use, namely when 
directed to prescribing by healthcare professionals and respiratory tract 
infections management [14]. 
Considering the already known benefits of both educational in-
terventions and e-health tools, an online course, eHealthResp, has been 
developed, especially directed to community pharmacists and physi-
cians. In sequence, the main objective of this study is to validate the 
contents of the online course eHealthResp [20] by using the Delphi 
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The eHealthResp online course is part of an educational intervention 
designed for community pharmacists and physicians. This intervention 
will take place on the catchment area of Portugal’s Centre Regional 
Health Administration (ARS-C), through a cluster randomised controlled 
trial. The project’s website, in which eHealthResp online course is 
embedded, has been already validated in terms of usability by phar-
macists [20], and will also be validated by physicians. 
2.2. eHealthResp online course 
eHealthResp [21] is an online course that provides a series of pre-
sentations addressing respiratory infections management. This online 
course’s main goal is to provide support to health practitioners partic-
ularly on upper respiratory tract infections management, which will 
consequently improve patients’ assistance and care. eHealthResp also 
includes a series of clinical cases to be solved at its end. The contents of 
the online course, composed by several presentations, provided clinical 
information on respiratory tract infections management, retrieved and 
adapted from national [22–24] and international [25–29] clinical 
practice guidelines, as well as from an online course already designed 
and developed in Spain for the same purpose [19]. Considering that 
most content was derived/extracted/obtained from up-to-date clinical 
practice guidelines, the only contents subjected to validation were the 
clinical cases to be included at the end of the online course. 
2.3. Phase I: Content validation questionnaire 
The questionnaire was composed of two main sections: demographic 
data and validation of the course contents [30,31]. The first section 
assessed gender, age, education level, medical specialty, and years of 
experience. The second section was initially composed by eight different 
clinical cases, each case being presented individually, as a subsection of 
the questionnaire. Experts were asked to determine which diagnosis, 
among the options provided, would fit best considering the information 
presented. Pharmacological and non-pharmacological therapy adequacy 
was also assessed, using a 5-point Likert scale, from “Very inadequate” 
to “Very adequate” [32–34]. An additional clinical practice question 
regarding delayed antibiotic therapy was added by authors on the last 
clinical case, as the positive impact of delayed antibiotic prescription 
was not unanimous on the literature [5,35]. At the end of each clinical 
case, panellists were also able to add observations if they deemed 
necessary. As all questions were of mandatory response, participants 
would only be able to proceed to the next section if they had responded 
to every question on the previous section/subsection. However, as some 
panellists did not answer to the last sections, the questions left unan-
swered by panellists were considered as missing cases for the purpose of 
data analysis. 
2.4. Phase II: Expert panel recruitment 
Nineteen experts were contacted via e-mail to participate in this 
Delphi study [31,36,37]. As this was a convenience sample, signed 
consents upon the use of e-mail contacts were obtained. Previously, and 
according to the General Data Protection Regulation (GDPR), each 
participant gave their informed consent for the questionnaires to be sent 
to their e-mails. Furthermore, before the filling of the questionnaire, 
each participant was informed about the objectives of this study and 
freely consented to participate in this study. The e-mail sent to the ex-
perts provided a hyperlink to the questionnaire. As the filling of the 
questionnaire was anonymous, the questionnaires respecting to both 
rounds were sent to the same nineteen experts. 
2.5. Phase III: Delphi method 
As the Delphi method allows for participation of a greater number of 
experts and flexibility, and direct communication between experts is not 
required, the two-round Delphi method was chosen in preference to 
other methods of consensus, such as the nominal group technique, 
which requires a maximum of seven panellists [38,39]. The Delphi 
technique is typically used for clinical practice guidelines drafting, as 
well as for finding uniform designations of terms for which there usually 
are conflicting judgments, thus being most appropriate approach for the 
validation of the online course contents. This study applied a modified 
Delphi method approach [40], consisting in the request of individual, 
anonymous information from each expert using a structured written 
questionnaire, in this case sent via e-mail, with two reminders, three 
weeks apart. Consensus for pharmacological and non-pharmacological 
treatments was obtained if the sum of the agreement percentages on 
“Very Adequate” and “Adequate, or ”Very Inadequate” and “Inade-
quate”. We considered consensus was obtained at [60–75%] (minor 
consensus) or ≥ 75% (full consensus) [30,41,42]. An example of a 
clinical case is provided on the supplementary material (Fig. S1). The 
suggestions given by the experts during the first round were considered 
and the clinical cases were reformulated accordingly. As there were 
reformulations between the first and second rounds, the approved 
clinical cases would be those that presented a higher agreement per-
centage and a higher number of respondents between each round. 
Hence, the treatments considered for the final model were those 
including the clinical cases with higher agreement between each round. 
The clinical cases with no agreement above 60% on either round were 
fully withdrawn from the online course contents. 
2.5.1. First Delphi round 
The questionnaire designed for the course evaluation initially con-
sisted of eight clinical cases. The first question for each clinical case 
presented eight options, corresponding to several respiratory tract 
conditions, and the participants were asked to answer which condition 
was more adequate as a diagnosis based on the information provided 
[32]. The second question of each clinical case presented thirteen 
pharmacological and non-pharmacological treatments [33,34]. Partici-
pants were asked to evaluate the adequacy of each treatment for each 
clinical case. The additional question on the last clinical case presented 
two options, out of which the participants would choose the one they 
considered the best in terms of clinical practice. An open question for 
further feedback was also included at the end of each clinical case. 
2.5.2. Second Delphi round 
After the first round, a report was sent to the participants presenting 
the results obtained in the first questionnaire and informing which 
percentage of agreement was obtained for each question [40]. This 
report presented each clinical case, followed by a graphical analysis of 
the agreement obtained for each response – both diagnosis and treat-
ment adequacy questions. The report allowed the experts to reconsider 
their points of view, as well as the convergence of contrasting opinions, 
thus obtaining maximum possible consensus. The questionnaire for the 
second round consisted of seven clinical cases, based on the reformu-
lations suggested by the panel. The first question for each clinical case 
presented seven options. The second question presented ten pharma-
cological and non-pharmacological treatments. The Fig. 1 below depicts 
the different phases of the two-round Delphi process: 
3. Results 
3.1. Expert panel characteristics 
Nineteen experts consented to participate on this study, and the 
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questionnaires were sent to all participants on both rounds [37]. As one 
of the panellists only responded to the second-round questionnaire, 
eighteen experts responded to the first round and nineteen to the second. 
Details on the characteristics of the panel are summed up in the Table 1: 
3.2. First Delphi round 
In the first Delphi round, 19 questionnaires were sent out. A total of 
18 questionnaires were answered. Consensus on the diagnosis was ob-
tained on 4 out of 8 clinical cases, one with minor consensus (61.11%), 
and the other 3 with >90% consensus. Regarding pharmacological and 
non-pharmacological treatment, most options (79.8%) obtained full 
consensus (≥70% agreement). The last question obtained 93.3% 
agreement. As there was a voluntary comment section after each clinical 
case, some experts provided feedback to improve both clinical cases and 
treatments. These observations were considered to clarify the clinical 
cases for round 2. Based on the feedback provided by experts on the first 
round, the clinical cases were reformulated, and one was removed. 
Pharmacological and non-pharmacological treatment was also clarified, 
with ten options instead of thirteen being currently presented. A second 
version of the questionnaire was then sent to participants. The first 
question for each clinical case presented seven options, corresponding, 
similarly to the questionnaire of the first round, to several respiratory 
tract conditions. The second question of each clinical case presented ten 
pharmacological and non-pharmacological treatments. The additional 
question on the last clinical case presented the same two options as the 
ones from round 1. 
3.3. Second Delphi round 
As participants were given the possibility to provide suggestions on 
the clinical cases during the first round, only 7 clinical cases have been 
presented on round 2. In the second round of the Delphi process, all 19 
questionnaires that were sent out, were answered. Consensus on the 
diagnosis was obtained on 4 out of 7 clinical cases, one with minor 
consensus (63.2%), and the remainder 3 with >90% consensus. As the 
second and third clinical cases were considered redundant by the panel, 
the third clinical case was not included on the second round. Most op-
tions (85.0%) regarding pharmacological and non-pharmacological 
treatment reached full consensus. However, as some options were 
considered redundant on the first round, they were merged in this sec-
ond round. Thus, the number of treatment options was reduced from 
thirteen to ten. The last question, associated to antibiotic treatment 
timing, obtained 94.7% agreement. 
Fig. 1. Schematic representation of the phases of the two-round Delphi study.  
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3.4. Validated contents 
After both rounds, consensus was obtained on most clinical cases. 
Two clinical cases, related to the common cold and the flu, were not 
validated, as the first clinical case, did not obtain consensus on either 
round, and the third clinical case was removed after the first round. 
Thus, the treatments provided for each of these clinical cases were also 
not validated. The Table 2 shows the comparison between the results on 
round 1 and round 2 of the Delphi process. As defined on the method-
ology, the clinical cases that were validated within the first round were 
the fourth, fifth, and sixth. The second, seventh and eight clinical cases 
(common cold, acute otitis media, and pharyngitis, respectively) were 
only validated in the second round. 
The Table 3 displays a matrix of the adequacy of each validated 
treatment for each clinical case, defining the pharmacological and non- 
pharmacological treatments that obtained consensus, either as very 
adequate/adequate or very inadequate/inadequate. Nine treatment 
options were validated with minor consensus [60–75%[, while other 
forty-two options were validated with full consensus (≥75%). As the 
clinical cases validated were derived from the first and second rounds, 
the treatments considered were those of each validated case. However, 
considering the redundancy of the options highlighted by the experts 
within the first round, ten treatment options were considered for both 
rounds. 
As observed on Table 3, each treatment was validated for at least two 
clinical cases. Moreover, although each clinical case had a minimum of 
one adequate treatment, the majority presented between 3 and 4 
adequate treatments. 
4. Discussion 
The two-round Delphi technique has allowed for the validation of the 
contents of the eHealthResp online course based on experts’ consensus. 
After the two-round Delphi technique, where most items have reached 
consensus [37,40,43], the contents of the online course eHealthResp 
were validated. The items that reached lower consensus were respecting 
to the first clinical cases (flu and common cold), which have shown to 
display similar clinical presentations to other upper respiratory tract 
infections [26–29]. One of the treatment options presenting lower 
agreement percentages was the one concerning antibiotic treatment, 
which emphasises the importance of educating health practitioners on 
conscientious antibiotic use for the treatment/management of respira-
tory tract infections [14,44,45]. 
The clinical cases that did not reach consensus were those corre-
sponding to the common cold and flu, thus reflecting the difficulty in 
differentiating these illnesses considering symptoms alone, and ambig-
uousness of the clinical presentations of these diseases [21,46], as well 
as between other respiratory tract infections [26–29]. Thus, considering 
the overlapping of symptoms of these illnesses, it becomes essential to 
emphasise the differential diagnosis between different respiratory tract 
infections [47]. Valuable feedback has been provided on both rounds, 
especially on the sections where it was made possible for experts to give 
suggestions. Although the majority of the comments were made on the 
first round, with these being further used to reformulate the clinical 
cases, some additional comments were also presented on the second 
round. These comments provided additional and very valuable infor-
mation, adapted to the current circumstances caused by the COVID-19 
pandemic (i.e., considering the difficulty in differentially diagnose 
infection from SARS-CoV-2 from other respiratory infections, some ex-
perts advised that, for some clinical cases, information on COVID-19 test 
results could also be included). 
The Delphi method was preferred to other methodologies that also 
aim to obtain consensus, such as the nominal group technique (NGT). It 
requires face-to-face meetings, while the Delphi technique is more 
flexible, being accessible to participants regardless of location, which 
made it possible to recruit a more diverse expert panel [39]. Further-
more, the Delphi method provides the possibility of recruiting a higher 
number of participants and, consequently, a more varied expert panel, 
as NGT usually requires a maximum of seven participants [39,41,48]. 
Additionally, as the Delphi technique is commonly used to develop 
guidelines with health professionals, we believe this technique was the 
most appropriate approach for the validation of the online course con-
tents, considering that NGT is usually employed to explore consumer 
and stakeholder views [39]. 
To our knowledge, although there are no known validated quality 
indicators for Delphi studies, one of the main strengths of this study is 
that it responded to each key methodologic criterium proposed on Di-
amond’s systematic review [41]. Despite there’s a high degree of 
freedom when it comes to the number of participants, the literature 
reports a median value similar to that of our study [41,48,49]. When 
considering similar methodologies, the number of rounds performed 
during the Delphi process tends to vary. Some studies only report one 
round, generally when a “real-time” Delphi approach is conducted [49, 
50]. Yet, most studies report two or three rounds, with a higher preva-
lence of the former [49]. Despite being in accordance with the literature, 
one of the limitations of this study can be the fact that only two rounds 
were conducted, as we would have possibly gotten a higher consensus 
Table 1 
Expert panel characteristics analysis.   






Age *45 (41, 56) 







Expertise area  
Infectious Diseases 
Pharmacology 




















Years of experience *20 (15, 32.5) 
Data are: n (%), *Median (PCT25, PCT75). 
Table 2 
Round 1 vs. round 2 results on diagnosis questions.   
Round  
First Second  
Rate Percentage Rate Percentage 
Clinical case 1 – Flu 8/18 44% 7/19 37% 
Clinical case 2 – Common cold 1 7/18 39% 12/ 
19 
63% 
Clinical case 3 – Common cold 2 9/18 50% – – 



























Question 8.1 – Antibiotic therapy 







M. Estrela et al.                                                                                                                                                                                                                                 
Biomedicine & Pharmacotherapy 140 (2021) 111739
5
rate on some of the clinical cases and/or obtain consensus on a higher 
number of validated clinical cases and respective treatment options if a 
higher number of rounds could have been carried out. Furthermore, 
regardless of the heterogeneity of the expert panel, increasing the 
number of participants would have possibly given more insightful 
feedback, especially at the end of the first round, where the question-
naire was restructured based on experts’ suggestions. The fact that this 
study was conducted during the COVID-19 pandemic and most panel-
lists were part of the main workforce combatting the effects of the 
pandemic, there was the need to send two reminders, as some experts 
had lower availability to answer the questionnaire. Still, practically all 
panellists have responded on both rounds, which emphasises the 
importance and the benefit in integrating these stakeholders on the 
development of educational material. 
Nevertheless, our study has another two main strengths: the high 
number of years of experience and the heterogeneity of the panel, which 
reflects the full range of stakeholders who have an interest in the out-
comes of this study. As different stakeholders generally have different 
points of view about clinical practice and quality of care, we believe the 
heterogenous feedback obtained within this study clearly enriched our 
results. The response rate obtained was also very positive (~95% on the 
first round and 100% on the second round), being in agreement with the 
literature [30,40]. 
5. Conclusions 
The aim of the online course is to aid health practitioners in respi-
ratory tract infections management. The validation of the contents on 
the online course eHealthResp certainly contributes to a great 
improvement of the educational intervention that will take place on a 
cluster randomised controlled trial, which will consequently not only 
have a positive impact on the research project’s outcomes but will also 
raise awareness on judicious antibiotic use for respiratory tract 
infections. 
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[14] É. Carvalho, M. Estrela, M. Zapata-Cachafeiro, A. Figueiras, F. Roque, M. 
T. Herdeiro, E-health tools to improve antibiotic use and resistances: a systematic 
review, Antibiotics 9 (8) (2020) 505 (Available from), 〈https://www.mdpi.com/ 
2079-6382/9/8/505〉. 
[15] F. Velickovski, L. Ceccaroni, J. Roca, F. Burgos, J.B. Galdiz, N. Marina, M. Lluch- 
Ariet, Clinical Decision Support Systems (CDSS) for preventive management of 
COPD patients, J. Transl. Med. 12 (2) (2014) 9, https://doi.org/10.1186/1479- 
5876-12-S2-S9. 
[16] M. António Ferreira Rodrigues Nogueira, H. Tygesen, H. Eriksson, J. Herlitz, 
Clinical decision support system (CDSS) – effects on care quality, Int J. Health Care 
Qual. Assur. 27 (8) (2014) 707–718 (Available from), 〈https://pubmed.ncbi.nlm. 
nih.gov/25417376/〉. 
[17] C.B. Litvin, S.M. Ornstein, A.M. Wessell, L.S. Nemeth, P.J. Nietert, Use of an 
electronic health record clinical decision support tool to improve antibiotic 
prescribing for acute respiratory infections: the ABX-TRIP study, J. Gen. Intern. 
Med. 28 (6) (2013) 810–816. 
[18] T.G. McGinn, L. McCullagh, J. Kannry, M. Knaus, A. Sofianou, J.P. Wisnivesky, D. 
M. Mann, Efficacy of an evidence-based clinical decision support in primary care 
practices: a randomized clinical trial, JAMA Intern. Med. 173 (17) (2013) 
1584–1591. 
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